Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Wuxi Biologics (Cayman) ( (HK:2269) ) has issued an announcement.
WuXi Biologics (Cayman) Inc. has announced a change in its principal place of business in Hong Kong, effective April 1, 2025. Additionally, the company has completed an asset transaction related to its Vaccines Ireland Facility, with a total consideration of approximately US$499.63 million. This transaction is expected to enhance WuXi Biologics’ capabilities in vaccine production, potentially strengthening its position in the global biologics market.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a company incorporated in the Cayman Islands, operating in the biotechnology industry. The company is focused on providing comprehensive services for biologics discovery, development, and manufacturing, with a particular emphasis on vaccine production.
YTD Price Performance: 71.30%
Average Trading Volume: 3,786
Technical Sentiment Signal: Sell
Current Market Cap: $14.15B
See more data about 2269 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue